A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies

Trial Profile

A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2018

At a glance

  • Drugs Ibrutinib (Primary) ; Umbralisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jun 2018 Pooled results from these trials (700216894, 700270293, 700239053, 700250580) are presented in a TG Therapeutics media release.
    • 15 Jun 2018 According to a TG Therapeutics media release, data from this study were presented at the 23rd Congress of the European Hematology Association (EHA).
    • 28 Mar 2018 Planned number of patients changed from 42 to 45.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top